Johnson & Johnson completed the acquisition of US-based Halda Therapeutics for $3 billion on December 29, 2025, advancing its prostate cancer treatment HLD-0915 through clinical development and approval.
| Acquirer | Johnson & Johnson (US) |
|---|---|
| Target | Halda Therapeutics (US) |
| Deal Value | $3.0bn |
| Stake Acquired | 100.0% |
| Type of Deal | Acquisition |
| Date Announced | 2025-11-17 |
| Close Date | 2025-12-29 |
| Buy-side Advisors (Financial) | Citi, Centerview Partners |
| Sell-side Advisors (Financial) | Canaccord Genuity |
| Buy-side Advisors (Legal) | Mayer Brown, Baker McKenzie, Goodwin Procter |
| Sell-side Advisors (Legal) | Latham & Watkins |
Deal Mechanics
The deal was structured as a $3 billion acquisition of Halda Therapeutics by Johnson & Johnson. The transaction was facilitated by financial advisors Citi and Centerview Partners for the buyer, with Canaccord Genuity providing advisory services to the seller. Legal counsel included Mayer Brown, Baker McKenzie, Goodwin Procter on the buy-side and Latham & Watkins representing the sell-side.
Strategic Rationale
The acquisition aims to bolster Johnson & Johnson's pipeline in prostate cancer treatments through Halda Therapeutics' novel drug HLD-0915. By acquiring Halda, J&J gains access to a promising clinical-stage asset that can potentially revolutionize the treatment landscape for patients with advanced and metastatic prostate cancer.
Financial Context
Halda Therapeutics was founded in 2019 by Tim Shannon of Canaan and Craig Crews from Yale University. The company raised significant investment to develop RIPTACs™, a class of therapeutics designed to induce cell death specifically within tumor cells, thereby minimizing side effects compared to traditional treatments.
Outlook
The acquisition is expected to accelerate the development and commercialization of HLD-0915. Johnson & Johnson's resources and expertise in oncology will be instrumental in advancing this promising treatment through clinical trials towards regulatory approval.